Navigation Links
PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
Date:9/7/2010

ANNAPOLIS, Md., Sept. 7 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) finalize its Proposed Rule regarding reimbursement to better ensure patient access to vital medicines in the hospital outpatient setting.

Specifically, for CY 2011, CMS proposes to set the payment level of separately payable non-pass-through drugs and biologicals, which include most plasma protein therapies, at average sales price (ASP) plus 6 percent. PPTA supports this proposal, believing that by setting payment rates at no less than ASP plus 6 percent, CMS will help ensure at this time that hospital outpatient departments remain a viable option for beneficiaries to receive therapies such as alpha-1 proteinase inhibitor, blood clotting factors and intravenous immune globulin (IVIG).

Furthermore, the proposed payment rate for hospital outpatient departments would put such products on par with the rates paid for pass-through drugs and biologicals in the physician office setting, thus, better assuring Medicare patients that they will have access to their necessary medications in either site of service.

"By matching payment levels in both the hospital outpatient department and the physician office, the choice of setting would be driven by clinical, not financial considerations, as it should be," said Julie Birkofer, Senior Vice President, PPTA North America.

Additionally, PPTA praised the agency's proposal to continue reimbursing hospitals for the "furnishing fee" for blood clotting factors, recommending that the proposal be made final.

While CMS' proposal makes strides with ensuring patient access to plasma protein therapies for small patient populations, PPTA continues to have concerns with the agency's flawed policy of using hospital claims data that includes drugs and biologicals sold as part of the heavily discounted 340B Drug Pricing Program when setting Outpatient Prospective Payment System (OPPS) payment rates. The 340B program limits the cost of covered outpatient drugs to certain federal grantees, federally-qualified health centers and qualified disproportionate share hospital.

In recent years, analysis of hospital claims data by multiple experts reveal that the inclusion of 340B hospitals when establishing rates artificially lowers the payment level that CMS generates, concluding that if CMS were to exclude 340B hospitals from its claims data analysis, the rate would more appropriately be as high as ASP plus 12 percent. This payment rate would be consistent with the calculation of other payment methodologies, including the ASP, the average manufacturer's price, and the best price. The Association continues to recommend that these data be removed from rate setting calculations.

PPTA appreciates the opportunity to comment on the Proposed Rule. The Association especially supports CMS' decision to continue the blood clotting factor furnishing fee in the OPPS for CY 2011 and urges the agency to finalize it with the pertinent update.

View PPTA's Comment Letter. For more information about PPTA, please visit www.pptaglobal.org.

The Plasma Protein Therapeutics Association (PPTA) represents the world's leading manufacturers of plasma-derived and recombinant biological therapies, collectively known as plasma protein therapies and the collectors of source plasma. These critical therapies are infused or injected by more than 1 million people worldwide to treat a variety of rare, life threatening diseases and serious medical conditions including hemophilia, primary immunodeficiency diseases and alpha-1 antitrypsin deficiency. PPTA members produce in excess of 80 percent of the plasma protein therapies used in the United States today and more than 60 percent worldwide. PPTA is a global trade association that administers international, voluntary standards programs to help ensure the highest quality and safety of plasma protein therapies and the plasma collected to manufacture them. Additionally, PPTA works in partnership with the patient community and consumer advocates to help ensure continued access to lifesaving plasma protein therapies.


'/>"/>
SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Clean Power Development, LLC Urges Sustainable, Community-Centric Approach to Biomass Energy
2. Tax Specialty Firm McGuire Sponsel Urges Qualifying Biotech Companies to Apply for New Qualifying Therapeutic Discovery Project Credit Soon
3. DuPont Science Leader Urges U.S. House Committee to Continue Federal Investment in Transformative, Clean Energy Technologies
4. VirtualHealth Technologies Will Change Its Name to VHGI Holdings, Inc. and Surges Forward Into Broader Market
5. Regional Biotech Association Urges Support for Biosimilars Bill in Congress
6. TechNet Urges Swift U.S. Senate Approval of FCC Nominees Julius Genachowski and Robert McDowell
7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
8. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
9. Beyond Turbidity: Selecting Appropriate Technology for in Situ Monitoring and Control of Complex Particle and Droplet Systems
10. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
11. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. Ltd. ... KRW (US $18.9M) Series A financing. This financing round ... Tech Venture and SNU Bio Angel. This new funding ... billion KRW (US $27.7M) since its founding in 2015. ... bolster the development and commercialization of its immuno-oncology programs, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... has concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid ... defining the optimal patient population and timing of blood sampling may improve the ...
(Date:12/7/2016)... 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces ... at the Company,s Annual and Special Meeting. ... place on Thursday, December 15, 2016 at Mount ... EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta ... meeting and management information circular, containing the matters to be ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced ... to the company,s Board of Directors. "We ... we build our business and develop our oncolytic viruses ... therapy," said Stephen Russell , MD, PhD, CEO ... , share our vision and passion for making a ...
Breaking Biology Technology:
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
Breaking Biology News(10 mins):